Press Releases

12.12.2016

Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company Focused on Oncolytic Cancer Vaccine Discovery and Development

12.09.2016

Akili and Pfizer Present Positive Data from Digital Biomarker Study to Detect Subtle Cognitive Changes in Healthy Subjects at Risk of Developing Alzheimer’s Disease

12.06.2016

Pfizer Announces Expansion of ASPIRE Awards Program for 2017 to Include $5.5M in Funding for Breast and Hematologic Cancers

12.05.2016

Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

12.03.2016

Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting

12.03.2016

New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

12.01.2016

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

12.01.2016

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

12.01.2016

LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

11.30.2016

Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab)

11.29.2016

FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review

11.21.2016

Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire